keyboard_arrow_up

In-Depth Insights on Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches is a new market research publication announced by Reportstack. This report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.

To access full report with TOC, please visit  Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020.

Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes - 
- A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis
- In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
- A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
- Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
- Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
- Discussion of the drivers and barriers for market growth
- In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to - 
- Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
- Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
- Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market"

About Reportstack:

Reportstack  is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack  members with cutting edge research products to facilitate strategic business decisions.

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###